Zealand Pharma Advances Oral Kv1.3 Blocker ZP9830 After Positive Phase 1a
Zealand Pharma has announced positive topline results from its Phase 1a trial of ZP9830, a novel Kv1.3 channel blocker. The study successfully met its primary objectives for safety and tolerability, paving the way for further development of this oral candidate for chronic inflammatory and autoimmune diseases.